351-30-4

Basic information

• Product Name: 4'-BROMO-3'-FLUOROACETANILIDE
• Synonyms: 4'-Bromo-3'-fluoroacetanilide, 98+%;4'-Bromo-3'-fluoroacetanlide;N-(4-Bromo-3-fluorophenyl)acetamide
• CAS NO: 351-30-4
• Molecular Formula: C₈H₇BrFNO
• Molecular Weight: 232.06
• Product Categories: Anilines, Amides & Amines;Bromine Compounds;Fluorine Compounds
• Mol File: 351-30-4.mol

Chemical Properties

• Melting Point: 149-152°C
• Boiling Point: 337.9°Cat760mmHg
• Flash Point: 158.1°C
• Appearance: /
• Density: 1.623g/cm³
• CAS DataBase Reference: 4'-BROMO-3'-FLUOROACETANILIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-BROMO-3'-FLUOROACETANILIDE(351-30-4)
• EPA Substance Registry System: 4'-BROMO-3'-FLUOROACETANILIDE(351-30-4)

Safety Data

• Hazard Codes: Xi
• Statements: 22
• Safety Statements: 22-36/37/39
• Hazardous Substances Data: 351-30-4(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
4'-Bromo-3'-Fluoroacetanilide is used as an intermediate in the synthesis of various organic compounds. Its unique structure, featuring both bromine and fluorine atoms, makes it a valuable building block for creating new molecules with specific properties.
Used in Pharmaceutical Applications:
In the pharmaceutical industry, 4'-Bromo-3'-Fluoroacetanilide serves as a key component in the development of drugs. Its presence in the molecular structure can influence the drug's activity, selectivity, and pharmacokinetics, contributing to the discovery of novel therapeutic agents.
Used in Research and Development:
4'-Bromo-3'-Fluoroacetanilide is also utilized in research settings to study the effects of halogen substitution on molecular properties and reactivity. Understanding these effects can lead to the design of more effective and safer pharmaceuticals and other chemical products.

Upstream product

• 656-65-5 3-fluoro-4-bromophenylamine 
• 108-24-7 acetic anhydride 
• 128-08-5 N-Bromosuccinimide 
• 372-19-0 meta-fluoroaniline 
• 351-28-0 N-(3-fluorophenyl)acetamide 

Downstream Products

• 1309365-71-6 6-bromo-7-fluoro-2-(4-methoxybenzylamino)quinoline-3-carbaldehyde 
• 1309365-72-7 (E)-methyl 3-(6-bromo-7-fluoro-2-(4-methoxybenzylamino)quinolin-3-yl)acrylate 
• 1309365-73-8 (E)-3-(6-bromo-7-fluoro-2-(4-methoxybenzylamino)quinolin-3-yl)-N-(cyclohexylmethyl)acrylamide 
• 1309365-74-9 3-(6-bromo-7-fluoro-2-(4-methoxybenzylamino)quinolin-3-yl)-N-(cyclohexylmethyl)propanamide 
• 1309365-75-0 N-(cyclohexylmethyl)-3-(7-fluoro-2-(4-methoxybenzylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-3-yl)propanamide 
• 1309365-76-1 N-(cyclohexylmethyl)-3-(7-fluoro-2-(4-methoxybenzylamino)-6-o-tolylquinolin-3-yl)propanamide 
• 1309364-62-2 3-(2-amino-7-fluoro-6-o-tolylquinolin-3-yl)-N-(cyclohexylmethyl)propanamide 
• 434960-42-6 5-bromo-6-fluoro-1H-indole 
• 1219741-80-6 4-bromo-5-fluoro-2-[(trimethylsilyl)ethynyl]aniline 
• 1219741-79-3 4-bromo-5-fluoro-2-iodoaniline 
• 153505-36-3 4-bromo-5-fluoro-2-nitroaniline 
• 3851-45-4 N-(4-bromo-3-fluoro-phenyl)-N'-phenyl-urea 
• 136434-79-2 1-Bromo-2-fluoro-4-pentylbenzene 
• 136434-78-1 1-bromo-2-fluoro-4-pent-1-ynylbenzene 

Relevant articles and documents

20-HETE FORMATION INHIBITORS

This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.

A para-C–H Functionalization of Aniline Derivatives via In situ Generated Bulky Hypervalent Iodinium Reagents

A practical para-C-H functionalization of aniline derivatives has been developed using an in situ generated bulky hypervalent iodinium reagent. Para-iodo, bromo, chloro, nitro, trifluormethyl aniline derivatives can be obtained efficiently, in many cases in 10 min in a transition metal-free manner. Medicinal chemicals or intermediates can be purified without column chromatography or recrystallization, which significantly reduces the waste and simplifies the work-up process.

Combining Eosin y with Selectfluor: A Regioselective Brominating System for Para-Bromination of Aniline Derivatives

A mild, metal-free, and absolutely para-selective bromination of aniline derivatives has been developed in excellent yields, wherein the organic dye Eosin Y is employed as the bromine source in company with Selectfluor. Neither air nor moisture sensitive, this facile reaction proceeds smoothly at room temperature and completes within a short time. Mechanistic studies indicate a radical pathway; therefore, the existence of an in situ generated brominating reagent, "Selectbrom", is postulated, which may reasonably account for the unique regioselectivity for the para-bromination of N-acyl- as well as N-sulfonylanilines.

SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Anisotropic organic compounds

STR1 The invention describes liquid crystalline compounds or formula (I), where A, D and G are independently selected from phenyl, thiophene, hydrogenated phenyl, chlorinated phenyl and fluorinated phenyl, B and E are independently selected from a single bond C= C. C C.C00, azoxy and diazo, k and m are independently selected from 1 and 0, such that m+n is 1 or 2, and R1 and R2 are independently selected from R, R0, alkynyl, thioalkyl, hydrogen, CN, NCS and SCN; provided that at least one of R1 and R2 is selected from CN, NCS and SCN and that at least one of A, D and G is phenyl; and excluding where at least one of R1 and R2 is independently selected as CN and one of A, D or G is not thiophene, and where m is 0, A, and D are phenyl, B is a single bond and only one of R1 or R2 is NCS. Also described are compounds suitable for inclusion in a device utilizing pretransitional characteristics of liquid crystalline materials in the isotropic phase, of general formula (II) where J and Y are independently selected from phenyl, thiophene, hydrogenated phenyl, chlorinated phenyl and fluorinated phenyl, X is selected from C= C. C C.COO azoxy and diazo, k is 1 or 0 and R3 and R4 are independently selected from R, RO, alkynyl, thioalkyl, hydrogen, CN, NCS and SCN; provided that at least one of R3 and R4 is selected from CN, NCS and SCN and that at least one of J and Y is phenyl.

The Synthesis of Several Lateral Difluoro-substituted 4,4''-Dialkyl- and 4,4''-Alkoxyalkyl-Terphenyls and a Rationalisation of the Effect of Such Substitution on Mesophase Type and Transition Temperatures

In recent years we have prepared a large number of mono-fluoro- and ortho-difluoro-substituted 4,4''-dialkyl- and 4,4''-alkoxyalkyl-terphenyls.The synthesis and transition temperatures of a variety of related difluoro compounds is presented here so that it is now possible to identify (i) broadening of the molecule, (ii) twisting about an inter-annular bond, and (iii) the presence of an "inner" (2-, 2'-, 3'- or 2''-substituent) or an "outer" (3- or 3''-substituent) fluorine, as being the major factors which influence the type and the thermal stability of the mesophases obtained.